In the future, our bispecific antibody may combine with cytokines enhancing NK proliferation and function such as interleukin-2 and interleukin-15 to potentiate NK-mediated ADCC against antibody-coated tumor cells and T regular cells. The gene discussed is IL2; the disease is neoplasm.